SELLAS Life Sciences Group, Inc. Interest Expense
SELLAS Life Sciences Group, Inc. (SLS) reported Interest Expense of $765.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2017-11-09
- SELLAS Life Sciences Group, Inc. interest expense for the quarter ending 2017-09-30 was $302.00K.
- SELLAS Life Sciences Group, Inc. interest expense for the quarter ending 2016-09-30 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month |
|---|---|---|---|
| 2017-09-30 | $302.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $765.00K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $463.00K 10-Q · filed 2017-08-14 | ||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |